Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models
Cancer Genomics - Proteomics · 2023
DOI: 10.21873/cgp.20368 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Genomics - Proteomics, 2023. Verfasst von Ulrich H Weidle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Development, Roche Innovation Center, Penzberg, Germany; weidle49@t-online.de fabian.birzele@roche.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roche Pharma Research and Development, Roche Innovation Center, Penzberg, Germany; weidle49@t-online.de fabian.birzele@roche.com.
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland weidle49@t-online.de fabian.birzele@roche.com.
Zitieren
APA
Weidle, U. H., & Birzele, F. (2023). Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models. Cancer Genomics - Proteomics. https://doi.org/10.21873/cgp.20368
Vancouver
Weidle UH, Birzele F. Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models. Cancer Genomics - Proteomics. 2023. doi:10.21873/cgp.20368
BibTeX
@article{Weidle2023,
author = {Weidle, Ulrich H and Birzele, Fabian},
title = {Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models},
journal = {Cancer Genomics - Proteomics},
year = {2023},
doi = {10.21873/cgp.20368}
}
EUVIMED